The recently concluded session had traders exchanging Calumet Specialty Products Partners, L.P. (NASDAQ:CLMT) low level. Roughly 0.25 million shares changed hands compared to the three-month volume average 0.42 million shares. The first trade took place at $7.1 and the stock went up 5.34% to attain the closing price of $7.4.Calumet Specialty Products Partners, L.P. (CLMT) Analyst Opinion
Calumet Specialty Products Partners, L.P. has a consensus hold rating from 5 Wall Street analysts, and the number of shares currently sold short amount to at least 0.5% of shares outstanding. The stock sank -3.9% last month and is down -3.9 this year. Wall Street is only getting neutral on the stock, with 1 of analysts who cover CLMT having a buy-equivalent rating. Analysts have placed a $8 price target on Calumet Specialty Products Partners, L.P., suggesting a 8.11% gain from recent close. It’s currently trading about -25.63% below its 52-week high.
Calumet Specialty Products Partners, L.P. (CLMT) failed to surprise the stock market in its last reported earnings when it earned -$0.3 a piece versus the consensus-estimated $0.25. Its revenue totaled $907.72 million down -11.95% from the previous quarter.Calumet Specialty Products Partners, L.P. (NASDAQ:CLMT) Intraday View
This stock (CLMT) is ahead of its 52-week low with 117.65%. Its last month’s stock price volatility remained 5.71% which for the week stands at 4.72%. The share price has moved backward from its 20 days moving average, trading at a distance of -3.47% and stays -5.67% away from its 50 days moving average. Over the last five days, shares have managed 1.37% gains and now is up 12.01% since hitting its 200-day moving average of $7.69. Calumet Specialty Products Partners, L.P. (CLMT) has made its way to a 12-month gain of 92.21%.
Turning to Portola Pharmaceuticals, Inc. (NASDAQ:PTLA), its shares were trading at $46.7 a gain of $2.29, on the trading floor. The stock, after opening at $44.63, touched a high of $47.335 before paring much of its gains. So far, analysts are sticking with their bullish recommendations with the consensus call at 1.6. Portola Pharmaceuticals, Inc. has 3 buy ratings, 0 holds and 0 sells even after the stock tumbled -30.4% from its high of $67.10 to a $3.06 billion market value through last close.
The company’s consensus rating on Reuter’s scale remained unchanged from 1.57 to 1.57 during a month. Analysts set a 12-month price target of $74.17 a share. The target implies a 58.82% spike from where the shares are currently trading. Also, the current price highlights a discount of 71.31% to analysts’ high consensus price target.Portola Pharmaceuticals, Inc. (NASDAQ:PTLA) Intraday Trading
The counter witnessed a trading volume of 0.71 million shares versus an average volume of 0.91 million shares during last trading session. Its last month’s stock price volatility remained 6.84% which for the week approaches 5.52%. The lowest price the stock reached in the last trading day was $44.63 and compares with the $27.12 52-week low. The stock recovered 72.2% since its low point and has performed -4.07% year-to-date.